Phase 4 N=192 Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery
ACL · Anterior Cruciate Ligament Injuries
Primary: Mean Opioid Consumption at 24 Hours — 21.5; 19.9 morphine milligram equivalents — p=0.17
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=59 Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
Excessive Daytime Sleepiness · Obstructive Sleep Apnea · Impaired Cognitive Function
Primary: Change From Baseline in the Average of the DSST RBANS Scores at the End of Each Double-blind Treatment Period — 6.49; 4.75 score on a scale — p=0.009
Phase 4 N=41 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Gastrointestinal Stromal Tumors
Primary: Proportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0. — 0; 14; 21; 6 Participants
Phase 4 N=196 A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain
Pain
Primary: Change From Baseline in the Average Minutes of Moderate and Vigorous Physical Activity (MVPA) at Week 1 — 249.2; 14.2 minutes — p=<0.001
Phase 4 N=59 Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: Change From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24 — -8.0 score on a scale
Phase 4 N=63 Systems Biological Assessment of Statin Effect on Vaccine Responses
Vaccine Response
Primary: Magnitude of the Antibody (Ab) Response to QIV in Statin Recipients and Non-recipients. — 1.33; 1.46; 1.35; 1.28 log fold-change (logFC)
Phase 4 N=500 A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
Obesity
Primary: Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no) — 132; 61; 75; 116 Participants — p=<0.0001
Phase 4 N=182 Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.
Dry Eye
Primary: Change in Ocular Surface Disease Index (OSDI) — 26.4; 26.3; 26.6; 16.4 score on a scale
Phase 4 N=79 A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
Central Precocious Puberty
Primary: Percentage of Participants With Peak Luteinizing Hormone (LH) Suppression in Gonadotropin-Releasing Hormone (GnRH) Stimulation at Week 24 — 97.47 percentage of…
Phase 4 N=170 Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor
Labor Long
Primary: Time to Delivery — 1041.8; 971.1 minutes
Phase 4 N=30 Peripheral Nerve Blocks for Above-the-knee Amputations
Peripheral Vascular Diseases · Hyperglycaemia (Diabetic) · Hypertension
Primary: Peripheral Nerve Block Success as a Primary Anesthetic — 1 Participants
Phase 4 N=245 Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance
Breast Cancer
Primary: Change in Endocrine Toxicity and Tolerability at 12 Weeks — -2.2; -5.0 units on a scale
Phase 4 N=53 Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
Alzheimer Disease
Primary: Change From Baseline Measure in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 8, 16 and 24 Weeks — 19.76; 19.81; 19.94; 20.79 scores on a scale…
Phase 4 N=14 Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
Cystic Fibrosis
Primary: Average Rate of Mucociliary Clearance (MCC) Over 60 Minutes — 14.8 percent cleared over 60 minutes — p=0.04
Phase 4 N=109 Pregabalin vs. Gabapentin on Reducing Opioid Usage
Analgesics · Gabapentin · Injuries
Primary: Reduction in Opioid Usage — 69.5; 81; 66.3 MME — p=0.687